

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Pastan et al.

**Application No.** 10/537,061

**Filed:** June 1, 2005

**Confirmation No.** 2145

**For:** RECOMBINANT IMMUNOTOXIN AND  
USE IN TREATING TUMORS

**Examiner:** David J. Blanchard

**Art Unit:** 1653

**Attorney Reference No.** 4239-67287-05

**SUBMITTED VIA EFS ON  
SEPTEMBER 24, 2007**

SUBMITTED VIA THE ELECTRONIC FILING SYSTEM  
COMMISSIONER FOR PATENTS

**INFORMATION DISCLOSURE STATEMENT PURSUANT TO  
37 C.F.R. § 1.97(d)**

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent. This Information Disclosure Statement ("IDS") is being filed after the date of a final action.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

This statement is provided in compliance with 37 C.F.R. § 1.97(e)(1). The undersigned hereby certifies that each item of information contained in the IDS filed herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the IDS.

Electronic payment by Deposit Account No. 02-4550, in the amount of \$180.00 is being submitted with this filing as required by 37 C.F.R. § 1.97(d) and as set forth in 37 C.F.R. § 1.17(p). Please charge any additional fees which may be required in connection with filing this IDS, or credit any overpayment, to Deposit Account No. 02-4550.


The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By



Susan Alpert Siegel, Ph.D.  
Registration No. 43,121

cc: Docketing; accounting